WEHI-345|1354825-58-3|-陌孚医药/Medlife

您当前的位置：

WEHI-345

目录号: PL11032 纯度: ≥98%

CAS No. :1354825-58-3

商品编号	规格	价格	会员价
PL11032-2mg	2mg	¥1591.00	请登录
PL11032-5mg	5mg	¥2652.00	请登录
PL11032-10mg	10mg	¥4178.00	请登录
PL11032-50mg	50mg	¥15108.00	请登录
PL11032-100mg	100mg	¥24109.00	请登录
PL11032-200mg	200mg	询价	询价
PL11032-500mg	500mg	询价	询价
PL11032-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2341.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	WEHI-345
中文别名	N-[2-[4-氨基-3-(4-甲基苯基)-1H-吡唑并[3,4-D]嘧啶-1-基]-2-甲基丙基]-4-吡啶甲酰胺;RIPK2抑制剂(WEHI-345);化合物WEHI345
英文名称	WEHI-345
英文别名	WEHI-345;N-[2-[4-Amino-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-2-methylpropyl]-4-pyridinecarboxamide;CS-2140;WHI-345;WEHI345;WEHI 345;4-Pyridinecarboxamide, N-[2-[4-amino-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-2-methylpropyl]-
Cas No.	1354825-58-3
分子式	C₂₂H₂₃N₇O
分子量	401.46
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	WEHI-345 是一种有效的选择性 RIPK2 激酶抑制剂，IC₅₀ 值为 0.13 μM。WEHI-345 在寡聚化结构域 (NOD) 刺激下可延迟 RIPK2 的泛素化和 NF-κB 的活化。
生物活性	WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC 50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation.
性状	Solid
IC50 & Target[1][2]	IC50: 0.13 μM (RIPK2 kinase)
体外研究(In Vitro)	WEHI-345 (500 nM; Raw 267.4 cells) is able to inhibit MDP-induced autophosphorylation activity of RIPK2 in cells. WEHI-345 (500 nM; 0 hour, 2 hours, 4 hours, 8 hours; BMDMs or THP-1 cells) potently blocks MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in bone marrow-derived macrophages (BMDMs). In THP-1 cells, WEHI-345 reduces mRNA levels of NF-kB targets such as TNF, IL-8, IL-1b and A20. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	WEHI-345 (20 mg/kg; intraperitoneal injection; twice daily; for 6 days; C57BL/6 male mice) treatment reduces disease score, inflammatory infiltrate, histological score and recruitment of dendritic cells to the site of inflammation. And improves body weight and reduces cytokine and chemokine levels, indicating an overall improvement of the condition in experimental autoimmune encephalomyelitis (EAE)-induced wild-type C57Bl/6 mice. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Nachbur U, et al. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nat Commun. 2015 Mar 17;6:6442.

溶解度数据	In Vitro: DMSO : 25 mg/mL (62.27 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation